Finally, we evaluated whether the inhibition of ERK5 could also affect the sensitivity of colon cancer cells to irinotecan and oxaliplatin, two cytotoxic agents currently used in 5-FU-based chemotherapy [1, 2]. The gene discussed is MAPK7; the disease is colonic neoplasm.